-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the CDE official website showed that Dongyang Pharmaceutical’s Class 1 new drug HEC88473 injection and Class 2 new drug Lurasidone delayed-release tablets have been approved for clinical use.
According to data from Minai.
com, since 2021, Dongyang Pharmaceutical has applied for the listing of 2 new drugs and 6 new drugs for clinical application (3 have been approved for clinical use).
Dongyang Pharmaceutical has recently been approved as a new clinical drug
Source: CDE official website
HEC88473 injection is a glucagon-like peptide-1 receptor (GLP-1)/fibroblast growth factor-21 (FGF21) dual agonist.
This class 1 new drug was first approved for clinical use on April 7, becoming the first GLP-1/FGF21 dual agonist approved for clinical use in China.
Lurasidone hydrochloride is an atypical antipsychotic with dual effects.
According to data from Meinenet, since 2021, Dongyang Pharmaceutical has applied for the listing of 2 new drugs, all of which are insulin; 6 new drugs have been applied for clinical trials, of which 3 have been approved for clinical use.
2021 Dongyang Pharmaceutical's application for listing/clinical new drugs
Source: Meinenet MED2.
Among the three approved clinical new drugs, insulin degludec injection is a new and ultra-long-acting insulin analog developed by Novo Nordisk, with global sales of 8.
